Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Despite many advances and optimization in colon cancer treatment, tumor recurrence and metastases make the development of new therapies necessary. Colon cancer stem cells (CCSCs) are considered as the main triggering factor of cancer progression, recurrence, and metastasis. CCSCs as a result of accumulated genetic and epigenetic alterations and also complex interconnection with the tumor microenvironment (TME) can evolve and convert to full malignant cells. Mounting evidence suggests that in cancer therapy both CCSCs and non‐CCSCs in TME have to be regarded to break through the limitation of current therapies. In this regard, stem cell capabilities of some non‐CCSCs may arise inside the TME condition. Therefore, a deep knowledge of regulatory mechanisms, heterogeneity, specific markers, and signaling pathways of CCSCs and their interconnection with TME components is needed to improve the treatment of colorectal cancer and the patient's life quality. In this review, we address current different targeted therapeutic options that target cell surface markers and signaling pathways of CCSCs and other components of TME. Current challenges and future perspectives of colon cancer personalized therapy are also provided here. Taken together, based on the deep understanding of biology of CCSCs and using three‐dimensional culture technologies, it can be possible to reach successful colon cancer eradication and improvise combination targeted therapies against CCSCs and TME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · cited 1×
“For a long time, it was shown that TME component and, specifically, immune reactions within it influence clinical outcome in human CRCs (Whiteside, 2008).”
BackgroundDependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Telomerase modulates Wnt signalling by association with target gene chromatin
Park, J.-I., Venteicher, A. S., Hong, J. Y., Choi, J., Jun, S., Shkreli, M., Chang, W., Meng, Z., Cheung, P., Ji, H., et al. (2009) · Nature · doi:10.1038/nature08137 · Cited by 707 · cited 2×
“Higher level of β‐catenin in the nucleus also causes the expression of telomerase reverse transcriptase that identified as a characteristic of CCSC (Park et al., 2009).”
BackgroundBecht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
The hypoxic tumor microenvironment: A driving force for breast cancer progression
Semenza, G. L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.036 · Cited by 535 · cited 1×
“Inhibition of HIF‐2α decreases tumorigenicity in most cancers (Semenza, 2016).”
BackgroundFang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190
The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells
Kim, H., Lin, Q., Glazer, P. M., & Yun, Z. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0944-8 · Cited by 122
Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma
Nouraee, N., Van Roosbroeck, K., Vasei, M., Semnani, S., Samaei, N. M., Naghshvar, F., Omidi, A. A., Calin, G. A., & Mowla, S. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073009 · Cited by 103
Organ-Tumor-on-a-Chip for Chemosensitivity Assay: A Critical Review
Kashaninejad, N., Nikmaneshi, M., Moghadas, H., Kiyoumarsi Oskouei, A., Rismanian, M., Barisam, M., Saidi, M., & Firoozabadi, B. (2016) · Micromachines · doi:10.3390/mi7080130 · Cited by 79 · cited 2×
“The organotypic model enables cancer scientists to study the effects of various factors of TME including inflammation to maximize the applicability of new drugs (Kashaninejad et al., 2016).”
BackgroundBioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer
Devarasetty, M., Skardal, A., Cowdrick, K., Marini, F., & Soker, S. (2017) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0397 · Cited by 41
The impact of pyrvinium pamoate on colon cancer cell viability
Wiegering, A., Uthe, F.-W., Hüttenrauch, M., Mühling, B., Linnebacher, M., Krummenast, F., Germer, C.-T., Thalheimer, A., & Otto, C. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1975-y · Cited by 37
Akbari, A., Amanpour, S., Muhammadnejad, S., Ghahremani, M. H., Ghaffari, S. H., Dehpour, A. R., Mobini, G. R., Shidfar, F., Abastabar, M., Khoshzaban, A., et al. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-47 · Cited by 33
Cited by
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Azwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Wang, Y., Liu, S., Chen, Y., Zhu, B., & Xing, Q. (2022) · World Journal of Oncology · doi:10.14740/wjon1446 · Cited by 17
“In the era of cancer precision medicine, cancer personalized therapy today could be much easier to be facilitated with the knowledge of cancer-specific genomics [3, 4].”
Background
Metadata
- Authors
- Jahanafrooz, Z., Mosafer, J., Akbari, M., Hashemzaei, M., Mokhtarzadeh, A., & Baradaran, B.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2019-10-24
- Volume
- 235
- Issue
- 5
- Pages
- 4153-4166
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2981712643
- Cited by
- 148
- References
- 15
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.